A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Active, not recruiting · NCT05929235 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma; Open Label; Oral Drug Administration | Active, not recruiting | Phase 1 | 2026-08-12 | NCT05929235 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Flare Therapeutics Inc. | 2 |
| Merck Sharp & Dohme LLC | 650 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Houston Methodist Cockrell Center for Advanced Therapeutics | Houston | United States | 1 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Mass General Cancer Center | Boston | United States | 5 |
| Memorial Slone Kettering Cancer Center | New York | United States | 2 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| Sylvester Comprehensive Cancer Center, University of Miami | Miami | United States | 3 |
| The Cleveland Clinic Foundation | Cleveland | United States | 55 |
| The University of Chicago Medicine | Chicago | United States | 14 |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | United States | 22 |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 9 |
| Yale Cancer Center | New Haven | United States | 15 |